G433 Predictors of insulin resistance and the effect of metformin treatment in obese paediatric patients. (27th April 2016)

• Record Type: Journal Article
• Authors: Gallen, H; Banerjee, I; Clayton, PE; Ehtisham, S; Padidela, R; Patel, L; Skae, M
• Is Part Of: Archives of disease in childhood. Volume 101(2016)Supplement 1
• Page Start: A256
• Page End: A256
• Publication Date: 2016-04-27
• Subjects: Children -- Diseases -- Periodicals; Infants -- Diseases -- Periodicals; 618.920005
• DOI: 10.1136/archdischild-2016-310863.421
• Languages: English
• ISSNs: 0003-9888

Abstract

Abstract : Aims: Paediatric obesity is a growing concern for the health service. There is currently no consensus for routine screening of metabolic profiles and medical treatment in obese paediatric patients. We aimed to determine medium-term outcomes of Metformin treatment on BMI, glucose and insulin levels in obese paediatric patients. Methods: In a retrospective review, data were collected from obese paediatric patients treated with Metformin for insulin resistance between October-09 and October-14. Demographic data was collected from these patients including presence of acanthosis nigricans (AN) and family history of T2DM. Changes in BMI SDS, glucose and insulin were analysed. Paired sample T-tests were used to compare pre and post treatment results (treatment washout period of 1 month). Results: 70 patients were treated with metformin (50=female) (35=British White, 18=Pakistani) at a mean age of 12.7 (6.1–17.2) years. Mean BMI 35.2 (24.2–48.5 kg/m 2 ) and BMI SDS 3.4 (2.2–4.7). All the patients had insulin resistance at start of treatment. 21 (30%) of these had both family history of T2DM and AN. An additional 22 patients had AN only (total with AN=43, 49%). Those with AN had significantly higher basal insulin levels (p < 0.05) than those without. Metformin was associated with reduced BMI z-score at 6–12 months (-0.1 SDS, p < 0.05) and 18–24 months (-0.2 SDS, p < 0.05). Reduction in fasting and postprandial glucose levels were (-0.1 mmol/L, p = 0.17) and (-0.5 mmol/L, p = 0.17) respectively, with a significant reduction in postprandial glucose levels in those patients with impaired glucose tolerance (n = 13) (-1.9 mmol/L, p < 0.05). Metformin was associated with a reduction in fasting insulin (-3.0 mU/L, p = 0.44), and significantly reduced 2 h insulin (-118.0 mU/L, p < 0.05) after treatment for 12–18 months. Conclusions: Acanthosis nigricans is a good clinical indicator for the presence of insulin resistance. Metformin treatment is significantly associated with reduction in BMI z-score from 6 months and reduced postprandial insulin levels after treatment. It should be considered as a treatment modality in normoglycaemic obese paediatric patients for weight stabilisation and improvement of insulin resistance, which may have longer term implications on metabolic health.